Clonmel, Ireland. April 23, 2021. Seroba’s portfolio company, Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in …
Dublin, Ireland. 14 April 2021. Seroba’s portfolio company, PQ Bypass Inc., a medical device pioneer advancing the treatment of complex peripheral artery disease (PAD), has been acquired by Endologix, a global medical device company wholly owned by investment firm Deerfield. Seroba was an early investor in PQ Bypass and co-led the Series A investment when …
Hamilton, ON and Boston. April 1, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donald A. Bergstrom, M.D., Ph.D., as a member of the Company’s Board of Directors. Dr Bergstrom, who currently serves as executive vice president, head of research …
Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors Read More »